Cargando…

Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies

Solid lipid nanoparticles (SLNs) are being extensively exploited as topical ocular carrier systems to enhance the bioavailability of drugs. This study investigated the prospects of drug-loaded SLNs to increase the ocular permeation and improve the therapeutic potential of clarithromycin in topical o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Anroop B., Shah, Jigar, Al-Dhubiab, Bandar E., Jacob, Shery, Patel, Snehal S., Venugopala, Katharigatta N., Morsy, Mohamed A., Gupta, Sumeet, Attimarad, Mahesh, Sreeharsha, Nagaraja, Shinu, Pottathil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068826/
https://www.ncbi.nlm.nih.gov/pubmed/33918870
http://dx.doi.org/10.3390/pharmaceutics13040523
_version_ 1783683093718106112
author Nair, Anroop B.
Shah, Jigar
Al-Dhubiab, Bandar E.
Jacob, Shery
Patel, Snehal S.
Venugopala, Katharigatta N.
Morsy, Mohamed A.
Gupta, Sumeet
Attimarad, Mahesh
Sreeharsha, Nagaraja
Shinu, Pottathil
author_facet Nair, Anroop B.
Shah, Jigar
Al-Dhubiab, Bandar E.
Jacob, Shery
Patel, Snehal S.
Venugopala, Katharigatta N.
Morsy, Mohamed A.
Gupta, Sumeet
Attimarad, Mahesh
Sreeharsha, Nagaraja
Shinu, Pottathil
author_sort Nair, Anroop B.
collection PubMed
description Solid lipid nanoparticles (SLNs) are being extensively exploited as topical ocular carrier systems to enhance the bioavailability of drugs. This study investigated the prospects of drug-loaded SLNs to increase the ocular permeation and improve the therapeutic potential of clarithromycin in topical ocular therapy. SLNs were formulated by high-speed stirring and the ultra-sonication method. Solubility studies were carried out to select stearic acid as lipid former, Tween 80 as surfactant, and Transcutol P as cosurfactant. Clarithromycin-loaded SLN were optimized by fractional factorial screening and 3(2) full factorial designs. Optimized SLNs (CL10) were evaluated for stability, morphology, permeation, irritation, and ocular pharmacokinetics in rabbits. Fractional factorial screening design signifies that the sonication time and amount of lipid affect the SLN formulation. A 3(2) full factorial design established that both factors had significant influences on particle size, percent entrapment efficiency, and percent drug loading of SLNs. The release profile of SLNs (CL9) showed ~80% drug release in 8 h and followed Weibull model kinetics. Optimized SLNs (CL10) showed significantly higher permeation (30.45 μg/cm(2)/h; p < 0.0001) as compared to control (solution). CL10 showed spherical shape and good stability and was found non-irritant for ocular administration. Pharmacokinetics data demonstrated significant improvement of clarithromycin bioavailability (p < 0.0001) from CL10, as evidenced by a 150% increase in C(max) (~1066 ng/mL) and a 2.8-fold improvement in AUC (5736 ng h/mL) (p < 0.0001) as compared to control solution (C(max); 655 ng/mL and AUC; 2067 ng h/mL). In summary, the data observed here demonstrate the potential of developed SLNs to improve the ocular permeation and enhance the therapeutic potential of clarithromycin, and hence could be a viable drug delivery approach to treat endophthalmitis.
format Online
Article
Text
id pubmed-8068826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80688262021-04-26 Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies Nair, Anroop B. Shah, Jigar Al-Dhubiab, Bandar E. Jacob, Shery Patel, Snehal S. Venugopala, Katharigatta N. Morsy, Mohamed A. Gupta, Sumeet Attimarad, Mahesh Sreeharsha, Nagaraja Shinu, Pottathil Pharmaceutics Article Solid lipid nanoparticles (SLNs) are being extensively exploited as topical ocular carrier systems to enhance the bioavailability of drugs. This study investigated the prospects of drug-loaded SLNs to increase the ocular permeation and improve the therapeutic potential of clarithromycin in topical ocular therapy. SLNs were formulated by high-speed stirring and the ultra-sonication method. Solubility studies were carried out to select stearic acid as lipid former, Tween 80 as surfactant, and Transcutol P as cosurfactant. Clarithromycin-loaded SLN were optimized by fractional factorial screening and 3(2) full factorial designs. Optimized SLNs (CL10) were evaluated for stability, morphology, permeation, irritation, and ocular pharmacokinetics in rabbits. Fractional factorial screening design signifies that the sonication time and amount of lipid affect the SLN formulation. A 3(2) full factorial design established that both factors had significant influences on particle size, percent entrapment efficiency, and percent drug loading of SLNs. The release profile of SLNs (CL9) showed ~80% drug release in 8 h and followed Weibull model kinetics. Optimized SLNs (CL10) showed significantly higher permeation (30.45 μg/cm(2)/h; p < 0.0001) as compared to control (solution). CL10 showed spherical shape and good stability and was found non-irritant for ocular administration. Pharmacokinetics data demonstrated significant improvement of clarithromycin bioavailability (p < 0.0001) from CL10, as evidenced by a 150% increase in C(max) (~1066 ng/mL) and a 2.8-fold improvement in AUC (5736 ng h/mL) (p < 0.0001) as compared to control solution (C(max); 655 ng/mL and AUC; 2067 ng h/mL). In summary, the data observed here demonstrate the potential of developed SLNs to improve the ocular permeation and enhance the therapeutic potential of clarithromycin, and hence could be a viable drug delivery approach to treat endophthalmitis. MDPI 2021-04-09 /pmc/articles/PMC8068826/ /pubmed/33918870 http://dx.doi.org/10.3390/pharmaceutics13040523 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nair, Anroop B.
Shah, Jigar
Al-Dhubiab, Bandar E.
Jacob, Shery
Patel, Snehal S.
Venugopala, Katharigatta N.
Morsy, Mohamed A.
Gupta, Sumeet
Attimarad, Mahesh
Sreeharsha, Nagaraja
Shinu, Pottathil
Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title_full Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title_fullStr Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title_full_unstemmed Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title_short Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
title_sort clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation, and in vivo studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068826/
https://www.ncbi.nlm.nih.gov/pubmed/33918870
http://dx.doi.org/10.3390/pharmaceutics13040523
work_keys_str_mv AT nairanroopb clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT shahjigar clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT aldhubiabbandare clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT jacobshery clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT patelsnehals clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT venugopalakatharigattan clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT morsymohameda clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT guptasumeet clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT attimaradmahesh clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT sreeharshanagaraja clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies
AT shinupottathil clarithromycinsolidlipidnanoparticlesfortopicaloculartherapyoptimizationevaluationandinvivostudies